Merck profit jumps on strong vaccine, cancer drug sales

55% rise in third-quarter profit

  
The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey, U.S., July 12, 2018.

The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey, U.S., July 12, 2018.

REUTERS/Brendan McDermid

U.S. drugmaker Merck & Co Inc reported a 55% rise in third-quarter profit on Thursday, helped by strong sales of blockbuster cancer drug Keytruda and recovery in demand for its non-COVID-19 vaccines, as well as lower expenses.

(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)


More From Health